For advanced metastatic non-small-lung cancer, the landscape of actionable driver
alterations is rapidly growing, with nine targetable oncogenes and seven approvals within …

Tumor immunotherapy has garnered considerable attention, emerging as a new standard of
care in cancer treatment. The conventional targets, such as VEGF and EGFR, have been …

Actionable mutations refer to DNA alterations that, if detected, would be expected to affect
patients' response to treatments [1]. Among these actionable mutations, the most clinically …

Background Non‐small cell lung cancer (NSCLC) patients harboring epidermal growth
factor receptor (EGFR)‐mutated who progressed on EGFR tyrosine‐kinase inhibitor (EGFR …

Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality
worldwide. The discovery of specific driver mutations has revolutionized the treatment …

The delivery of neoadjuvant and perioperative therapies for non-small cell lung cancer has
been radically altered by significant advances and by the incorporation of targeted therapies …

Co-occurring genetic alterations in solid tumors are a critical and influential prognostic factor
that holds substantial importance in understanding the disease progression and guiding …

Background The dynamic interplay between tyrosine kinase inhibitors (TKIs) and the tumor
immune microenvironment (TME) plays a crucial role in the therapeutic trajectory of non …

Die neoadjuvante und perioperative Therapie des nicht kleinzelligen Lungenkarzinoms
(NSCLC) hat sich durch bedeutende Fortschritte und die Einbeziehung von zielgerichteten …

SLC40A1+ macrophages contribute to the immunosuppressive tumor microenvironment in
EGFR-mutated lung cancer SLC40A1 + macrophages contribute to the immunosuppressive …